Western University to release preliminary study results of Trudell COPD therapy device

A new device designed to help people suffering from chronic obstructive pulmonary disease (COPD) and other lung diseases developed by Trudell Medical International has been clinically tested by researchers at Western University and preliminary results will be revealed tomorrow (Tuesday, January 28) at the Robarts Research Institute in London, Ontario.  

The Aerobika Oscillating Positive Expiratory Pressure (OPEP) Therapy System is a drug-free, easy to use, hand-held device that aims to help people with lung disease breathe easier.

Dr. David McCormack and Grace Parraga from Western’s Schulich School of Medicine & Dentistry and members of their research team, as well as Trudell Medical Group CEO Mitch Baran, will be available to discuss the findings on Tuesday, January 28 at 11:30 a.m. at Robarts’ Imaging Research Laboratories.

Members of the media will have an opportunity to tour the imaging lab and speak with Baran, the researchers, as well as a study participant that used the COPD device.

Media are asked to meet in the Robarts’ lobby at 11:20 a.m. to allow time to register with security. Parking is available in front of Robarts but be advised most of the area is restricted for vehicles. A member of Western’s media relations team will coordinate.

Parraga is also set to present at the Better Breathing Conference 2014, which is being held at the Marriott Downtown Eaton Centre in Toronto from Friday, January 31 to Saturday, February 1. Representatives from Trudell will also be attending.

Globally, COPD is the fourth leading cause of death. An estimated 600-million suffer from the lung disease, including 2.35 to 5 million Canadians.    

MEDIA CONTACT: Jeff Renaud, Senior Media Relations Officer, 519-661-2111, ext. 85165, jrenaud9@uwo.ca, @jeffrenaud99

Western delivers an academic experience second to none. Since 1878, The Western Experience has combined academic excellence with life-long opportunities for intellectual, social and cultural growth in order to better serve our communities. Our research excellence expands knowledge and drives discovery with real-world application. Western attracts individuals with a broad worldview, seeking to study, influence and lead in the international community.

MEDIA CONTACT: Mark Pickard, Vice President and General Manager, 519-455-7060, ext. 2200, mpickard@trudellmed.com

TMI designs, develops and manufactures a wide range of medical devices, from our flagship AeroChamber* Brand of Valved Holding Chamber (VHC) for asthma patients and our latest state-of-the-art Aerobika* OPEP therapy system for COPD patients, to custom designed products and systems. Our best-in-class respiratory management products are sold in over 100 countries worldwide and their efficacy has been validated in over 500 peer-reviewed articles from various medical journals. TMI is registered to ISO 13485 Standard, specific for medical device manufacturers.

*trademarks and registered trademarks of Trudell Medical International.